A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer

Published:2021-07 Issue: Volume:157 Page:21-29
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Fung A.S.^ORCID,Graham D.M.,Chen E.X.^ORCID,Stockley T.L.,Zhang T.^ORCID,Le L.W.,Albaba H.,Pisters K.M.,Bradbury P.A.,Trinkaus M.^ORCID,Chan M.,Arif S.^ORCID,Zurawska U.,Rothenstein J.,Zawisza D.,Effendi S.,Gill S.,Sawczak M.,Law J.H.,Leighl N.B.

Funder

Novartis Pharmaceuticals Canada Inc

Array Biopharma Inc

Princess Margaret Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. MAP kinase signalling pathways in cancer;Dhillon;Oncogene,2007

2. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors;Tolcher;Mol. Cancer Ther.,2018

3. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations;Hyman;N. Engl. J. Med.,2015

4. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicenter, open-label, phase 2 trial;Planchard;Lancet Oncol.,2016

5. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol.,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01

2. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors;International Review of Cell and Molecular Biology;2024

3. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations;Lung Cancer;2023-09

4. Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks;International Journal of Molecular Sciences;2023-01-23

5. KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration;Journal of Clinical Medicine;2023-01-16